MX2021001252A - Partículas de modificación inmunitaria para el tratamiento del cáncer. - Google Patents

Partículas de modificación inmunitaria para el tratamiento del cáncer.

Info

Publication number
MX2021001252A
MX2021001252A MX2021001252A MX2021001252A MX2021001252A MX 2021001252 A MX2021001252 A MX 2021001252A MX 2021001252 A MX2021001252 A MX 2021001252A MX 2021001252 A MX2021001252 A MX 2021001252A MX 2021001252 A MX2021001252 A MX 2021001252A
Authority
MX
Mexico
Prior art keywords
cancer
modifying particles
treatment
tumor
immune
Prior art date
Application number
MX2021001252A
Other languages
English (en)
Inventor
John Puisis
Original Assignee
Oncour Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncour Pharma Inc filed Critical Oncour Pharma Inc
Publication of MX2021001252A publication Critical patent/MX2021001252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona métodos para el tratamiento del cáncer y las enfermedades proliferativas mediante el uso de partículas de modificación inmunitaria en combinación con el producto terapéutico contra el cáncer, tales como inhibidores del punto de control inmunitario o agentes biológicos, para modificar la actividad de células supresoras derivadas de mieloides (MDSC), macrófagos asociados al tumor (TAM), neutrófilos, monocitos y/o estroma asociado al tumor relacionados con la promoción del crecimiento tumoral y metástasis.
MX2021001252A 2018-07-31 2019-07-31 Partículas de modificación inmunitaria para el tratamiento del cáncer. MX2021001252A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712604P 2018-07-31 2018-07-31
US201962788569P 2019-01-04 2019-01-04
PCT/US2019/044454 WO2020028544A1 (en) 2018-07-31 2019-07-31 Immune modifying particles for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021001252A true MX2021001252A (es) 2021-05-27

Family

ID=69230909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001252A MX2021001252A (es) 2018-07-31 2019-07-31 Partículas de modificación inmunitaria para el tratamiento del cáncer.

Country Status (11)

Country Link
EP (1) EP3829548A4 (es)
JP (1) JP2021532136A (es)
KR (1) KR20210053891A (es)
CN (1) CN112823001A (es)
AU (1) AU2019312589A1 (es)
BR (1) BR112021001858A2 (es)
CA (1) CA3107134A1 (es)
IL (1) IL280468A (es)
MX (1) MX2021001252A (es)
SG (1) SG11202100700VA (es)
WO (1) WO2020028544A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020322046A1 (en) * 2019-07-31 2022-03-10 Oncour Pharma, Inc. Treatment of immune evasive tumors
CN112410302B (zh) * 2020-11-10 2023-02-17 福建医科大学 基于多靶标组合的肿瘤干细胞的富集和筛选方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
JP6725413B2 (ja) * 2013-03-13 2020-07-15 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 炎症の治療のための免疫修飾粒子

Also Published As

Publication number Publication date
CA3107134A1 (en) 2020-02-06
BR112021001858A2 (pt) 2021-05-04
EP3829548A4 (en) 2022-05-04
KR20210053891A (ko) 2021-05-12
AU2019312589A1 (en) 2021-02-04
JP2021532136A (ja) 2021-11-25
WO2020028544A1 (en) 2020-02-06
SG11202100700VA (en) 2021-02-25
IL280468A (en) 2021-03-01
CN112823001A (zh) 2021-05-18
EP3829548A1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MX2020007046A (es) Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
PH12018500869A1 (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12019550027A1 (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
EA201991214A1 (ru) Антитела против pd-1 и их композиции
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2017005553A (es) Terapia de combinacion para cancer.
EP3964527A3 (en) Combination therapy for cancer
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
GB2518908A (en) Materials and methods for treating PTEN mutated or deficient cancer
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
MX2016013910A (es) Tratamiento del cancer.
MX2021001252A (es) Partículas de modificación inmunitaria para el tratamiento del cáncer.
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
PH12018502381A1 (en) Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.